Metastatic prostate cancer is prostate cancer that has spread beyond the prostate gland to other parts of the body. About 9% of prostate cancer cases are already metastatic at the time of diagnosis, and the five-year relative survival rate for this stage is roughly 40%, according to the National Cancer Institute’s SEER database. That number has been improving as treatments advance, and many men live well beyond that benchmark depending on where the cancer has spread and how it responds to therapy.
Where Prostate Cancer Spreads
Prostate cancer has a strong preference for bone. Roughly 85% to 90% of prostate cancer metastases are found in the skeleton, most commonly in the spine, pelvis, ribs, and upper legs. The reason is partly biological: bone tissue is constantly being broken down and rebuilt, and that remodeling process releases growth factors that create a hospitable environment for prostate cancer cells. Once cancer cells settle in bone, they stimulate even more bone turnover, creating a self-reinforcing cycle of tumor growth.
Unlike many other cancers that eat away at bone, prostate cancer tends to trigger abnormal new bone formation. These are called osteoblastic lesions. The new bone is structurally weak despite appearing dense on imaging, which is why fractures remain a serious risk. Cancer cells also increase bone breakdown at the same time, so patients experience both processes simultaneously.
Beyond bone, prostate cancer can spread to lymph nodes (both nearby and distant), the lungs, liver, and less commonly the brain. The specific sites of spread matter because they influence symptoms, treatment options, and outlook.
How Staging Works
Metastatic prostate cancer falls under Stage IV, which is divided into two substages. Stage IVA means the cancer has spread to nearby lymph nodes but hasn’t reached distant organs. Stage IVB means the cancer has traveled to distant sites like bones or lymph nodes far from the prostate. The distinction matters for treatment planning: Stage IVA disease may still be treated more aggressively with intent to control it locally, while Stage IVB requires systemic therapy aimed at the whole body.
Symptoms of Bone Metastases
Many men with metastatic prostate cancer first notice persistent bone pain, particularly in the lower back, hips, or thighs. This pain often worsens at night or with activity and doesn’t respond well to typical pain relievers. But bone metastases can cause problems beyond pain. The most serious complications include pathological fractures (bones breaking from normal activity because they’ve been weakened by cancer), spinal cord compression (tumor growth pressing on the spinal cord, which can cause weakness or numbness in the legs and requires urgent treatment), and radiation or surgery to stabilize damaged bone.
Some men also experience fatigue, unintentional weight loss, and difficulty urinating if the primary tumor is large. When cancer spreads to the liver or lungs, symptoms related to those organs may appear, but bone-related problems dominate the clinical picture for most patients.
How It’s Detected
A rising PSA level is often the first signal that prostate cancer has spread or returned after treatment. But PSA alone can’t show where the cancer is. Imaging plays a critical role, and the technology has improved significantly in recent years.
PSMA PET scans represent a major advance over conventional CT scans and bone scans. These scans target a protein found on the surface of prostate cancer cells, allowing detection of small metastases that older imaging methods miss entirely. PSMA PET is particularly good at finding small lymph node involvement and early bone metastases, giving doctors a more complete picture of how far the cancer has spread. The scan has a specificity around 94% when compared against surgical confirmation, meaning false positives are uncommon. Its sensitivity for detecting individual lymph node metastases is more modest at about 54%, largely because very tiny deposits can still escape detection.
Hormone Therapy as the Foundation
Prostate cancer cells rely on testosterone to grow. The cornerstone of metastatic prostate cancer treatment is cutting off that fuel supply through hormone therapy, also called androgen deprivation therapy. This can be done with injections that shut down testosterone production or, more recently, with an oral medication that accomplishes the same thing. The goal is to drop testosterone to what’s called castration level, below 50 nanograms per deciliter.
On top of basic hormone therapy, most men with metastatic disease now receive a second, more powerful hormone-blocking drug. These newer agents block testosterone from reaching cancer cells at the receptor level, adding another layer of suppression. They’re typically started at the same time as initial hormone therapy rather than held in reserve, because clinical trials showed this combination significantly extends survival compared to hormone therapy alone.
When Cancer Stops Responding to Hormones
Over time, prostate cancer cells can adapt and grow even when testosterone is suppressed to very low levels. This is called castration-resistant prostate cancer. The first sign is often a rising PSA despite ongoing hormone therapy, or new areas of cancer appearing on imaging scans. There isn’t a single PSA cutoff that defines castration resistance. Instead, doctors look at the overall trend: if testosterone is confirmed to be at castration level and the cancer is still progressing, the disease has become resistant.
Castration-resistant metastatic prostate cancer is harder to treat but far from untreatable. Several additional therapies are available at this stage, and the sequence depends on what treatments were used earlier, the patient’s overall health, and the genetic profile of the tumor.
Genetic Testing and Targeted Therapy
Current guidelines strongly recommend that all patients with metastatic prostate cancer undergo genetic testing, both of the tumor itself and of inherited (germline) DNA. This isn’t optional or experimental; it’s considered standard of care because the results directly affect treatment decisions.
The most important findings involve mutations in DNA repair genes, particularly BRCA1 and BRCA2 (the same genes linked to breast and ovarian cancer risk). Men whose tumors carry these mutations tend to have more aggressive disease, but they also qualify for a class of targeted drugs called PARP inhibitors that exploit the cancer’s inability to repair its own DNA. These drugs can be used alone or combined with hormone-blocking therapy. Platinum-based chemotherapy is another option for men with these mutations. If initial genetic testing comes back negative, repeat testing may be offered later if the cancer changes behavior or if the original sample was too small to be informative.
Radioligand Therapy
One of the newer treatment options uses a targeted radioactive compound that seeks out prostate cancer cells wherever they are in the body. The drug, known commercially as Pluvicto, attaches to the same protein (PSMA) used in PET scanning, delivering radiation directly to cancer cells while largely sparing healthy tissue.
The FDA initially approved this therapy for men who had already been through both hormone-blocking drugs and chemotherapy. In 2025, that approval was expanded to include men with PSMA-positive castration-resistant metastatic prostate cancer who have progressed on hormone-blocking therapy but haven’t yet needed chemotherapy. In the clinical trial supporting this expansion, men who received the radioligand therapy went a median of 9.3 months before their cancer progressed, compared to 5.6 months for those who switched to a different hormone-blocking drug. Before starting treatment, patients undergo a PSMA PET scan to confirm their cancer cells express enough of the target protein for the therapy to work.
Living With Metastatic Prostate Cancer
The treatment landscape for metastatic prostate cancer has shifted dramatically over the past decade. Men diagnosed today have access to more effective hormone therapies, genetic testing that matches them to targeted drugs, advanced imaging that catches spread earlier, and entirely new categories of treatment like radioligand therapy. The five-year survival rate of about 40% reflects cases diagnosed across a range of years and treatments, and outcomes for men starting current therapies are likely better than that number suggests.
Side effects from ongoing hormone therapy are a daily reality for most men and include hot flashes, fatigue, loss of muscle mass, bone thinning, weight gain, and changes in mood or sexual function. Bone-strengthening medications are commonly used alongside cancer treatment to reduce the risk of fractures, particularly when metastases have already reached the skeleton. Managing these side effects is a central part of care, not an afterthought, because treatment for metastatic prostate cancer is typically continuous rather than time-limited.